Chronic inflammation, which is partly mediated via the interleukin 6 (IL-6) pathway, has been hypothesized to play a critical role in the pathophysiology of type 2 diabetes (T2D) [1,2]. Here, IL6 is linked to type 2 diabetes mellitus.